Zymeworks Inc.

Zymeworks Inc.

26.45
USD
+0.21
(+0.80%)
0.58EPS
45.05P/E
1.90BMarket Cap
Mar 10Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.08
0.49
0.56
2.44
1.82
0.78
0.77
0.41
6.33
1.1
1.01
1.41
3.61
Basic EPS, GAAP
-0.65
-0.97
-1.74
-0.51
-1.26
-3.83
-3.58
-3.25
1.91
-1.72
-1.62
-1.08
0.59
Free Cash Flow per Basic Share
-0.37
-1.16
-2.07
-0.14
0.71
-2.52
-3.13
-3.16
2.01
-1.78
-1.49
-0.47
-1.53
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
0.93
0.46
4.58
5.64
6.21
8.9
4.23
7.82
6.63
4.91
3.57
3.6
Tangible Book Value per Share
- -
0.92
-1.2
3.35
4.64
5.31
8.15
3.66
7.21
6.1
4.67
3.39
-4.03
Basic Weighted Avg Shares
20
20
20
21
29
38
50
52
65
69
76
75
74
Sales/Revenue/Turnover
2
10
11
52
53
30
39
21
412
76
76
106
266
Operating Margin (%)
-763.35
-206.63
-336.96
-15.32
-62.93
-509.49
-481.25
-808.37
31.63
-181.56
-157.03
-87.33
16.63
Depreciation Expense
- -
- -
1
3
4
7
10
8
12
17
11
11
9
Net Income, GAAP
-13
-19
-34
-10
-37
-145
-181
-168
124
-119
-123
-81
43
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
8.05
- -
- -
- -
- -
Profit Margin (%)
-774.97
-198.45
-307.1
-20.1
-68.95
-492.27
-463.54
-794.01
30.14
-156.13
-160.8
-76.56
16.28
Working Capital
- -
13
30
78
174
229
369
171
449
357
212
206
371
LT Debt
- -
- -
4
- -
- -
6
6
25
25
22
16
15
41
Total Equity
- -
18
9
116
180
246
410
197
493
465
339
269
258
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
31.55
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
33.44
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
-252.04
-17.42
-24.62
-68.25
-55.08
-55.23
36.04
-24.78
-30.54
-26.72
14.98

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
3
3
12
LT Borrowings
- -
- -
- -
LT Finance Leases
14
13
41
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
74
72
72
Market Capitalization
1,844
1,881
1,900

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
386
298
532
Cash, Cash Equivalents & STI
365
271
100
Accounts Receivable, Net
5
6
414
Inventories
- -
- -
- -
Total Current Liabilities
36
47
161
Payables & Accruals
30
28
132
ST Debt
3
3
12
Deferred Revenue
2
16
17

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
134.53%
8.92%
-20.74%
Free Cash Flow
-177.48%
-89.4%
-68.74%
Net Income, GAAP
17.32%
-81.45%
-33.88%
Sales/Revenue/Turnover
213.98%
353.14%
38.87%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
10
19
16
31
76
2025
27
49
28
3
106
2026
2
5
256
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.42
-0.49
-0.39
-0.31
-1.62
2025
-0.3
0.03
-0.26
-0.55
-1.08
2026
-0.59
-0.62
2.43
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Kenneth Harry Galbraith
Full Time Employees
264
Sector
Health technology
Industry
Pharmaceuticals: major
Address
108 Patriot Drive Middletown DE United States 19709
IPO Date
Jun 24, 2019
Business
Zymeworks Inc. (Nasdaq: ZYME) is a clinical-stage biotechnology company that develops and commercializes multifunctional biotherapeutics targeting difficult-to-treat cancers and other diseases. The company engineers Azymetric and Zymabod platforms to create bispecific antibodies and multispecific antibody-based molecules; its product candidates include zanidatamab, a HER2-targeting bispecific antibody in Phase 3 trials for biliary tract cancer partnered with Jazz Pharmaceuticals, as well as ZW171, ZW220, and other preclinical and early-stage assets targeting solid tumors and hematologic malignancies. Zymeworks offers contract research and development services through its subsidiaries, focusing on protein engineering and therapeutic design for oncology and autoimmune indications. Founded in 2010 and headquartered in Vancouver, Canada, the company operates primarily in North America with clinical trials and partnerships extending to Europe and Asia. In the last two years, Zymeworks completed a significant strategic transaction with Iconic Therapeutics in 2024, acquiring full global rights to zanidatamab and related HER2-targeted programs following Jazz Pharmaceuticals' return of rights in late 2023, enabling accelerated independent development. The company raised approximately CAD 92 million through a public offering in 2024 to fund zanidatamab's Phase 3 HERIZON-BTC-01 trial and other pipeline advancement. Zymeworks also advanced ZW171 into a Phase 1 trial in 2025 for advanced or metastatic solid tumors, marking a key expansion of its ROR1-targeted portfolio, while streamlining operations to focus on high-potential clinical assets amid a challenging biotech funding environment.

Company News

  • Zymeworks Announces $200 Million Share Repurchase Authorization

  • Zymeworks Inc. (ZYME) Misses Q3 Earnings Estimates

  • Zymeworks Provides Corporate Update and Reports Third Quarter 2026 Financial Results

  • Comparing Vericel (NASDAQ:VCEL) and Zymeworks (NASDAQ:ZYME)

  • Zymeworks Inc. (ZYME) to Report Q3 Results: Wall Street Expects Earnings Growth

  • Zymeworks Highlights ZW191 Ovarian Cancer Responses, Roche Deal Upside

  • Zymeworks Inc. (ZYME) Discusses Portfolio Strategy, Roche Partnership and Pipeline Updates Transcript

  • Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors

  • Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026

  • Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3

  • Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma

  • Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Results

  • Zymeworks Completes Theravance Deal, Adds YUPELRI Cash Flow and Raises 2026 Outlook

  • Zymeworks Inc. (ZYME) M&A Call Transcript

  • Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition

  • Bank of America Corp DE Buys 219,071 Shares of Zymeworks Inc. $ZYME

  • Zymeworks Completes Acquisition of Theravance Biopharma

  • Zymeworks Inc. (ZYME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

  • Jupiter Topco LLC Buys New Position in Zymeworks Inc. $ZYME

  • Zymeworks: Transitioning Into A Royalty-Driven Biopharma Platform Post Ziihera Approval